NF-kappaB inhibitors in treatment and prevention of lung cancer.
NF-kappaB inhibitors in treatment and prevention of lung cancer.
复制标题
DOI：
10.1016/j.biopha.2020.110569
复制
发表时间：
2020-10-01
期刊：
影响因子：
--
通讯作者：
Guruvayoorappan, Chandrasekaran
中科院分区：
文献类型：
--
作者：
Rasmi, Rajan Radha;Sakthivel, Kunnathur Murugesan;Guruvayoorappan, Chandrasekaran
细胞内信号通路为药物开发提供了极好的资源，特别是在癌症治疗剂的开发中。人类常见的多种恶性肿瘤表现出异常的NF-κ B组成型表达，其导致多种实体瘤（包括胰腺癌、肺癌、宫颈癌、前列腺癌、乳腺癌和胃癌）中的肿瘤发生过程和癌症存活。大量的证据表明，NF-κ B信号传导机制主要参与了几种癌症的进展，这可能会加强对它在疾病特别是肺癌发生中的作用的认识。这导致了大量的研究，设计各种NF-κ B拮抗剂，通过不同的方法增强临床应用，最常见的是抑制IkappaB激酶（IKK）β活性。许多用于肺癌的NF-κ B抑制剂现在正在进行临床试验。其中几种药物的临床试验的初步结果包括小分子抑制剂和单克隆抗体。一些组合治疗疗法目前正在临床研究中，并已显示出前景，特别是与肺癌相关的NF-κ B抑制。
Intracellular signalling pathways have provided excellent resource for drug development particularly in the development of cancer therapeutics. A wide variety of malignancies common in human exhibit aberrant NF-kappaB constitutive expression which results in tumorigenic processes and cancer survival in a variety of solid tumour, including pancreatic cancer, lung, cervical, prostate, breast and gastric carcinoma. Numerous evidences indicate that NF-kappaB signalling mechanism is mainly involved in the progression of several cancers which may intensify an enhanced knowledge on its role in disease particularly lung tumorigenesis. This has led to tremendous research in designing a variety of NF-kappaB antagonists with enhanced clinical applications through different approaches the most common being suppression of IkappaB kinase (IKK) beta activity. Many NF-kappaB inhibitors for lung cancer are now under clinical trials. Preliminary results of clinical trials for several of these agents include small-molecule inhibitors and monoclonal antibodies. A few combinatorial treatment therapies are currently under investigation in the clinics and have shown promise, particularly NF-kappaB inhibition associated with lung cancer.